Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 91

Sort by

Sort Order Select

Journal Articles

Acalabrutinib treatment for older (aged ≥80 years) and/or frail patients with CLL: primary end point analysis of the CLL-Frail trial

Blood (2025) 146 (26): 3153–3162.

https://doi.org/10.1182/blood.2025028550

Published: 2025

Includes: Supplemental data

Journal Articles

The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL

Blood (2025) 146 (20): 2406–2416.

https://doi.org/10.1182/blood.2025028899

Published: 2025

Includes: Supplemental data

Journal Articles

Fixed-duration versus continuous targeted treatment for previously untreated chronic lymphocytic leukemia: Results from the randomized CLL17 trial

Othman Al-Sawaf, Janina Stumpf, Can Zhang, Florian Simon, Francesc Bosch Albareda, Emadoldin Feyzi, Paolo Ghia, Michael Gregor, Arnon Kater, Vesa Lindström, Mattias Mattsson, Carsten Niemann, Philipp Staber, Tamar Tadmor, Patrick Thornton, Clemens-Martin Wendtner, Ann Janssens, Thomas Noesslinger, Jan-Paul Bohn, Caspar da Cunha-Bang, Christian Poulsen, Juha Ranti, Thomas Illmer, Bjoern Schoettker, Sebastian Böttcher, Tobias Gaska, Elisabeth Vandenberghe, Ruth Clifford, Ohad Benjamini, Annamaria Frustaci, Lydia Scarfo, Paolo Sportoletti, John Schreurs, Mark-David Levin, Hanneke van der Straaten, Marjolein van der Klift, Hoa Tran, Javier de la Serna, Javier Loscertales, Oscar Lindblad, Anna Bergendahl Sandstedt, Jeroen Goede, Michael Baumann, Anna Maria Fink, Kirsten Fischer, Matthias Ritgen, Karl-Anton Kreuzer, Christof Schneider, Eugen Tausch, Stephan Stilgenbauer, Sandra Robrecht, Barbara Eichhorst, Michael Hallek

Blood (2025) 146 (Supplement 1): 1.

https://doi.org/10.1182/blood-2025-1

Published: 2025

Journal Articles

Efficacy of 2nd-line treatment in CLL after venetoclax-based 1st-line treatment: Results from the GAIA/CLL13 trial

Blood (2025) 146 (Supplement 1): 795.

https://doi.org/10.1182/blood-2025-795

Published: 2025

Journal Articles

Correlates of response to combined checkpoint and BTK inhibition for treatment of richter transformation: Extended follow-up from the prospective RT1 trial

Blood (2025) 146 (Supplement 1): 90.

https://doi.org/10.1182/blood-2025-90

Published: 2025

Journal Articles

Epcoritamab monotherapy demonstrates promising efficacy in patients with Richter transformation (RT): 2-year follow-up results from arm 2A of the phase 1b/2 EPCORE CLL-1 trial

Arnon Kater, Ann Janssens, Herbert Eradat, Fritz Offner, Jose D. Sandoval-Sus, Mazyar Shadman, Christian Poulsen, Jacob Christensen, Meghan Thompson, Meijian Guan, Andrew J. Steele, Marcia Rios, Marie Holst Mørch, Toshihiko Oki, Rebecca Valentin, Mar Bellido, Barbara Eichhorst

Blood (2025) 146 (Supplement 1): 1017.

https://doi.org/10.1182/blood-2025-1017

Published: 2025

Journal Articles

A phase 3, randomized, open-label, multicenter study of sonrotoclax (BGB-11417) plus anti-CD20 antibody therapies vs venetoclax plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL-RR1/CELESTIAL-RRCLL)

Blood (2025) 146 (Supplement 1): 2137.

https://doi.org/10.1182/blood-2025-2137

Published: 2025

Journal Articles

Redefining early vs late progressive disease (PD) in chronic lymphocytic leukemia: A pooled analysis of fixed-duration therapies

Blood (2025) 146 (Supplement 1): 2107.

https://doi.org/10.1182/blood-2025-2107

Published: 2025

Journal Articles

Updated efficacy and safety results of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory Waldenström macroglobulinemia from the ongoing phase 1 CaDAnCe-101 study

Constantine Tam, Chan Cheah, John Seymour, Ricardo Parrondo, Mazyar Shadman, Damien Roos Weil, Stephan Stilgenbauer, Barbara Eichhorst, Herbert Eradat, Steven Treon, Yanan Zhang, Linlin Xu, Kunthel By, Shannon Fabre, Motohisa Takai, Amit Agarwal, Annamaria Frustaci

Blood (2025) 146 (Supplement 1): 3583.

https://doi.org/10.1182/blood-2025-3583

Published: 2025

Journal Articles

Impact of prognostic mutations on outcomes with fixed-duration acalabrutinib-venetoclax combinations versus chemoimmunotherapy: An exploratory analysis from AMPLIFY

Paolo Ghia, Barbara Eichhorst, Tomasz Wrobel, Inci Alacacıoğlu, Ana Rita da Fonseca, Dennis Carney, Guillaume Cartron, Alina Gerrie, Don Stevens, Marianne de Borja, Toshifumi Fujimori, Ellie John, L. Alex Liggett, Gary De Jesus, Veerendra Munugalavadla, Jennifer Brown

Blood (2025) 146 (Supplement 1): 3898.

https://doi.org/10.1182/blood-2025-3898

Published: 2025

Journal Articles

MRD-guided venetoclax-obinutuzumab in CLL: Final analysis of the CLL2-bag trial of the gcllsg

Paula Cramer, Léa Mazot, Sandra Robrecht, Adam Giza, Anna Maria Fink, Julia Von Tresckow, Petra Langerbeins, Florian Simon, Moritz Fürstenau, Othman Al-Sawaf, Kirsten Fischer, Eugen Tausch, Ludwig Fischer von Weikersthal, Clemens-Martin Wendtner, Sebastian Böttcher, Matthias Ritgen, Stephan Stilgenbauer, Barbara Eichhorst, Michael Hallek

Blood (2025) 146 (Supplement 1): 5668.

https://doi.org/10.1182/blood-2025-5668

Published: 2025

Journal Articles

Distinct archetypes of clonal dynamics underlie response and resistance to diverse CLL therapies

Blood (2025) 146 (Supplement 1): 245.

https://doi.org/10.1182/blood-2025-245

Published: 2025

Journal Articles

Pre-existing cytotoxic capacity of CD8+ and CD4+ T cells is a hallmark of richter transformation and favors response to anti-PD-1 therapy

Blood (2025) 146 (Supplement 1): 243.

https://doi.org/10.1182/blood-2025-243

Published: 2025

Journal Articles

Hitting the therapeutic bull’s-eye with targeted therapy for patients with chronic lymphocytic leukemia

William G. Wierda, Barbara Eichhorst, Michael Hallek

Blood (2025) 146 (7): 779–788.

https://doi.org/10.1182/blood.2025028570

Published: 2025

Journal Articles

International consensus statement on diagnosis, evaluation, and research of Richter transformation: the ERIC recommendations

Blood (2025) 146 (3): 291–303.

https://doi.org/10.1182/blood.2024028064

Published: 2025

Includes: Supplemental data

Journal Articles

The MURANO study: final analysis and retreatment/crossover substudy results of VenR for patients with relapsed/refractory CLL

Blood (2025) 145 (23): 2733–2745.

https://doi.org/10.1182/blood.2024025525

Published: 2025

Includes: Supplemental data

Journal Articles

MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trial

Blood (2025) 145 (12): 1282–1292.

https://doi.org/10.1182/blood.2024026685

Published: 2025

Includes: Supplemental data

Journal Articles

Sustained benefit of zanubrutinib vs ibrutinib in patients with R/R CLL/SLL: final comparative analysis of ALPINE

Blood (2024) 144 (26): 2706–2717.

https://doi.org/10.1182/blood.2024024667

Published: 2024

Includes: Supplemental data

Journal Articles

Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study

Blood (2024) 144 (18): 1924–1935.

https://doi.org/10.1182/blood.2024024631

Published: 2024

Includes: Supplemental data

Journal Articles

Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial

Blood (2024) 144 (3): 272–282.

https://doi.org/10.1182/blood.2023022730

Published: 2024

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Acalabrutinib treatment for older (aged ≥80 years) and/or frail patients with CLL: primary end point analysis of the CLL-Frail trial

The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL

Fixed-duration versus continuous targeted treatment for previously untreated chronic lymphocytic leukemia: Results from the randomized CLL17 trial

Efficacy of 2nd-line treatment in CLL after venetoclax-based 1st-line treatment: Results from the GAIA/CLL13 trial

Correlates of response to combined checkpoint and BTK inhibition for treatment of richter transformation: Extended follow-up from the prospective RT1 trial

Epcoritamab monotherapy demonstrates promising efficacy in patients with Richter transformation (RT): 2-year follow-up results from arm 2A of the phase 1b/2 EPCORE CLL-1 trial

A phase 3, randomized, open-label, multicenter study of sonrotoclax (BGB-11417) plus anti-CD20 antibody therapies vs venetoclax plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL-RR1/CELESTIAL-RRCLL)

Redefining early vs late progressive disease (PD) in chronic lymphocytic leukemia: A pooled analysis of fixed-duration therapies

Updated efficacy and safety results of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory Waldenström macroglobulinemia from the ongoing phase 1 CaDAnCe-101 study

Impact of prognostic mutations on outcomes with fixed-duration acalabrutinib-venetoclax combinations versus chemoimmunotherapy: An exploratory analysis from AMPLIFY

MRD-guided venetoclax-obinutuzumab in CLL: Final analysis of the CLL2-bag trial of the gcllsg

Distinct archetypes of clonal dynamics underlie response and resistance to diverse CLL therapies

Pre-existing cytotoxic capacity of CD8+ and CD4+ T cells is a hallmark of richter transformation and favors response to anti-PD-1 therapy

Hitting the therapeutic bull’s-eye with targeted therapy for patients with chronic lymphocytic leukemia

International consensus statement on diagnosis, evaluation, and research of Richter transformation: the ERIC recommendations

The MURANO study: final analysis and retreatment/crossover substudy results of VenR for patients with relapsed/refractory CLL

MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trial

Sustained benefit of zanubrutinib vs ibrutinib in patients with R/R CLL/SLL: final comparative analysis of ALPINE

Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study

Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only